Solid Tumors Archives - Page 3 of 6

Four more companies secured their place on the stock ticker in a record-breaking year before 2020 comes to a close.

December 11, 2020/by Andrew Humphreys

Bayer Leaps into CAR T-Cell Therapy Scene with Atara Biotherapeutics Collaboration

Business, CAR-T Therapy, Cell Therapy, Collaborations, Deals, Gene Therapy, Immunotherapies, R&D, Solid Tumors, T-Cells

Days after Bayer announced a new cell and gene therapy strategy to maximize the capabilities of some recent acquisitions, the Germany-based life sciences giant is jumping into the CAR-T space and expanding the company’s oncology focus through a collaboration with Bay Area-based Atara Biotherapeutics.

December 7, 2020/by Andrew Humphreys

Urovant’s Irritable Bowel Drug Fails in Phase II; Genmab Abandons Cancer Drug

Abdominal Pain, Antibody-Drug Conjugates (ADCs), Biomarkers, Business, Cancer, Clinical Trials, Irritable Bowel Syndrome with Diarrhea (IBS-D), Monoclonal Antibodies, Product Pipelines, R&D, Shares, Small Molecules, Solid Tumors, Topline Data

Urovant Sciences and Genmab reported disappointing clinical trial announcements.

November 25, 2020/by BioSpace

Merck to bolster cancer drug portfolio with VelosBio $2.75 billion deal

Acquisitions, Blockbusters, Business, Cancer, Clinical Trials, Equity Stake, Hematologic malignancies, R&D, Shares, Solid Tumors, Therapeutics

Merck & Co. Inc. agreed to acquire privately held VelosBio Inc. for $2.75 billion in cash, in a move that will help strengthen the company’s cancer drug portfolio.

November 5, 2020/by Andrew Humphreys

FDA Awards Fast Track Designation to Multiple Non-Covid-19 Candidates

Acid Disorders, Acute repetitive seizures, Coronavirus Disease (COVID-19) Pandemic, Fast Track Designation, FDA, Gene Therapy, Hypogammaglobulinemia, Imaging Agents, Infections and Myelokathexis) syndrome, Methylmalonic Acidemia (MMA), MPS Type VI, Non-Small Cell Lung Cancer (NSCLC), Phenylketonuria (PKU), Primary Mitochondrial Myopathy (PMM), Solid Tumors, WHIM (Warts

While the world has largely been focused on the development of vaccines and therapeutics for Covid-19, the U.S. Food and Drug Administration has remained busy lining up potential approvals of medications for other diseases and illnesses.

November 4, 2020/by Andrew Humphreys

Karyopharm Therapeutics Eyes New Indication in Solid Tumors for Xpovio

Business, Dedifferentiated Liposarcoma, Immunomodulatory Agents, R&D, Shares, Solid Tumors, Therapeutics, Topline Data

Shares of Karyopharm Therapeutics climbed in trading after the company announced positive topline results in a Phase III study of Xpovio (selinexor) in patients with advanced unresectable dedifferentiated liposarcoma, which sets up potential approval in this indication.

November 3, 2020/by Andrew Humphreys

Amgen’s KRAS Inhibitor Sotorasib Effective in Non-Small Cell Lung Cancer

Advanced Non-Small Cell Lung Cancer, Cancer, Chemotherapy, Clinical Trials, Immunotherapies, KRAS G12C Mutations, Overall Response Rate (ORR), R&D, RAS Genes, Solid Tumors

Amgen presented positive topline data from the Phase II CodebreaK 100 trial of sotorasib in KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC).

October 6, 2020/by Andrew Humphreys

Opdivo Significantly Improves DFS vs. Placebo as Adjuvant Therapy for Patients with High-Risk, Muscle-Invasive Urothelial Carcinoma

Blockbusters, Clinical Trials, Disease-Free Survival (DFS), Immunotherapies, Metastatic Urothelial Carcinoma (mUC), PD-1/PD-L1 inhibitors, Placebo, Primary Endpoints, R&D, Solid Tumors, Therapeutics, Tumors

Bristol Myers Squibb announced that CheckMate -274, a pivotal Phase 3 trial evaluating Opdivo (nivolumab) after surgery in patients with high-risk, muscle-invasive urothelial carcinoma, met primary endpoints of improving disease-free survival (DFS) versus placebo in both all randomized patients and in patients whose tumor cells express PD-L1 ≥1% (programmed death-ligand 1).

September 24, 2020/by Andrew Humphreys

Merck and Seattle Genetics Ink Two New Strategic Cancer Collaborations

Antibody-Drug Conjugates (ADCs), Blockbusters, Business, Cancer, Checkpoint Inhibitors, Clinical Trials, Collaborations, Deals, HER2 protein, Investments, Licensing, Oncology, Premarket Trading, R&D, Small Molecules, Solid Tumors, Triple Negative Breast Cancer (TNBC), Tyrosine kinase inhibitors

Seattle Genetics’ shares rocketed after news broke of Merck making a major investment into the Bothwell, Washington-based company via two strategic oncology deals.

September 14, 2020/by Andrew Humphreys

Gilead Sciences to Acquire Immunomedics

Acquisitions, Antibody-Drug Conjugates (ADCs), Business, First-In-Class, Metastatic Breast Cancer, Shares, Solid Tumors, Therapeutics

Gilead Sciences Inc. and Immunomedics announced that the companies entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share in cash.

September 13, 2020/by Andrew Humphreys